|
ActiveSite Pharmaceuticals utilizes
proprietary lead discovery technology
to discover new small molecule drug candidates (NCEs) for human diseases with
unmet medical need. Our initial efforts are focused on developing novel,
innovative treatments for diabetic macular edema and hemorrhagic stroke by targeting the vascular serine protease plasma kallikrein.
Technology
Clinical Indications
Plasma Kallikrein
Founders
Publications & News
Contact Us
|
|